(Q83171950)

English

Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors

scientific article published on 04 January 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22215532%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22215532%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22215532%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

C Massard

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22215532%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

R Salazar

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22215532%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

J P Armand

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22215532%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

M Majem

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22215532%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

M García

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22215532%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

A Oaknin

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22215532%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

E M Fernández-García

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22215532%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

A Soto

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22215532%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

J C Soria

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22215532%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

4 January 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22215532%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22215532%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

30

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22215532%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22215532%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

2318-2326

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22215532%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

https://scigraph.springernature.com/pub.10.1007/s10637-011-9772-8

0 references

A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/22215532

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://pubmed.ncbi.nlm.nih.gov/22215532

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A more sensitive MS detector does not obviously lead to a more sensitive assay: experiences with ES-285.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22215532

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Kahalalide F and ES285: potent anticancer agents from marine molluscs.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22215532

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantitative analysis of ES-285, an investigational marine anticancer drug, in human, mouse, rat, and dog plasma using coupled liquid chromatography and tandem mass spectrometry.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22215532

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Compatibility and stability of the novel anticancer agent ES-285 x HCl formulated with 2-hydroxypropyl-beta-cyclodextrin in infusion devices

1 reference

https://pubmed.ncbi.nlm.nih.gov/22215532

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/22215532

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/22215532

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmaceutical development of a parenteral lyophilised formulation of the investigational anticancer agent ES-285.HCl.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22215532

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Spisulosine (ES-285) induces prostate tumor PC-3 and LNCaP cell death by de novo synthesis of ceramide and PKCzeta activation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22215532

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The marine sphingolipid-derived compound ES 285 triggers an atypical cell death pathway

1 reference

https://pubmed.ncbi.nlm.nih.gov/22215532

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The marine compound spisulosine, an inhibitor of cell proliferation, promotes the disassembly of actin stress fibers.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22215532

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q83171950&oldid=1411790153"